CN100430056C - Mglur5拮抗剂在制备治疗gerd的药物中的用途 - Google Patents

Mglur5拮抗剂在制备治疗gerd的药物中的用途 Download PDF

Info

Publication number
CN100430056C
CN100430056C CNB038141760A CN03814176A CN100430056C CN 100430056 C CN100430056 C CN 100430056C CN B038141760 A CNB038141760 A CN B038141760A CN 03814176 A CN03814176 A CN 03814176A CN 100430056 C CN100430056 C CN 100430056C
Authority
CN
China
Prior art keywords
metabotropic glutamate
glutamate receptor
antagonist
preparation
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038141760A
Other languages
English (en)
Chinese (zh)
Other versions
CN1662235A (zh
Inventor
A·勒曼恩
J·马特森
T·M·茨多曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20288301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100430056(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1662235A publication Critical patent/CN1662235A/zh
Application granted granted Critical
Publication of CN100430056C publication Critical patent/CN100430056C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNB038141760A 2002-06-20 2003-06-19 Mglur5拮抗剂在制备治疗gerd的药物中的用途 Expired - Fee Related CN100430056C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0201943-8 2002-06-20
SE02019438 2002-06-20
SE0201943A SE0201943D0 (sv) 2002-06-20 2002-06-20 New use

Publications (2)

Publication Number Publication Date
CN1662235A CN1662235A (zh) 2005-08-31
CN100430056C true CN100430056C (zh) 2008-11-05

Family

ID=20288301

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038141760A Expired - Fee Related CN100430056C (zh) 2002-06-20 2003-06-19 Mglur5拮抗剂在制备治疗gerd的药物中的用途

Country Status (24)

Country Link
EP (1) EP1513525B1 (enExample)
JP (2) JP4683920B2 (enExample)
CN (1) CN100430056C (enExample)
AT (1) ATE395059T1 (enExample)
AU (1) AU2003241585B2 (enExample)
BR (1) BR0311759A (enExample)
CA (1) CA2489730C (enExample)
CY (1) CY1107954T1 (enExample)
DE (1) DE60320990D1 (enExample)
DK (1) DK1513525T3 (enExample)
ES (1) ES2304510T3 (enExample)
IL (1) IL165138A0 (enExample)
IS (1) IS7654A (enExample)
MX (1) MXPA04012659A (enExample)
NO (1) NO20050154L (enExample)
NZ (1) NZ536559A (enExample)
PL (1) PL372186A1 (enExample)
PT (1) PT1513525E (enExample)
RU (1) RU2324484C2 (enExample)
SE (1) SE0201943D0 (enExample)
SI (1) SI1513525T1 (enExample)
UA (1) UA81627C2 (enExample)
WO (1) WO2004000316A1 (enExample)
ZA (1) ZA200409908B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
SE0303418D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
WO2005060971A1 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of reflux-related diseases
WO2005060961A2 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
WO2005077368A2 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
CN1918154A (zh) * 2004-02-18 2007-02-21 阿斯利康(瑞典)有限公司 多杂环化合物及其作为代谢型谷氨酸受体拮抗剂的用途
RU2006128445A (ru) * 2004-02-18 2008-03-27 Астразенека Аб (Se) Ацетилиновые пиперазиновые соединения и их применение в качестве антагонистов метаботропных глутаматных рецепторов
GB0514296D0 (en) * 2005-07-12 2005-08-17 Novartis Ag Organic compounds
SI2001849T1 (sl) * 2006-03-29 2015-02-27 F. Hoffmann-La Roche Ag Derivati piridina in pirimidina kot antagonisti mglur2
KR20090061041A (ko) 2006-09-11 2009-06-15 노파르티스 아게 대사성 글루타메이트 수용체의 조절제로서의 니코틴산 유도체
JP2008245225A (ja) * 2007-03-29 2008-10-09 Kddi Corp 波長パス経路決定装置、波長パス設定制御システム及びプログラム
WO2009024491A1 (en) * 2007-08-20 2009-02-26 F. Hoffmann-La Roche Ag Use of mglur5 antagonists for the treatment of gerd
EP2826478A1 (en) 2008-06-30 2015-01-21 Novartis AG Combinations comprising mglur modulators for the treatment of parkinson's disease
WO2011009890A2 (en) 2009-07-23 2011-01-27 Novartis Ag Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
EP2490691A1 (en) 2009-10-20 2012-08-29 Novartis AG Use of 1h-quinazoline-2,4-diones
RU2013103001A (ru) 2010-06-24 2014-07-27 Новартис Аг Применение 1н-хиназолин-2,4-дионов
US20140171448A1 (en) 2011-01-27 2014-06-19 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
WO2013036224A1 (en) 2011-09-07 2013-03-14 Novartis Ag Use of 1h-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy
BR112015016994A8 (pt) 2013-01-15 2018-01-23 Novartis Ag uso de agonistas do receptor alfa 7 nicotínico de acetilcolina
WO2014111837A1 (en) 2013-01-15 2014-07-24 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
US20220387410A1 (en) * 2019-11-05 2022-12-08 Claes Thulin 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine for use in prevention and/or treatment of surmenage in a mammal

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036057A (en) * 1986-01-03 1991-07-30 The University Of Melbourne Method of treating gastroesophageal reflux
WO1999059612A1 (en) * 1998-05-15 1999-11-25 Aphton Corporation Method for the treatment of gastroesophageal reflux disease
US6117908A (en) * 1996-09-18 2000-09-12 Astra Aktiebolag Use of GABAB receptor agonists as reflux inhibitors
WO2001012627A1 (en) * 1999-08-19 2001-02-22 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2144331C1 (ru) * 1998-11-05 2000-01-20 Московский НИИ уха, горла и носа Способ лечения хронического гиперпластического ларингита
US7115630B2 (en) * 2000-10-02 2006-10-03 Janssen Pharmaceutica N.V. Metabotropic glutamate receptor antagonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036057A (en) * 1986-01-03 1991-07-30 The University Of Melbourne Method of treating gastroesophageal reflux
US6117908A (en) * 1996-09-18 2000-09-12 Astra Aktiebolag Use of GABAB receptor agonists as reflux inhibitors
WO1999059612A1 (en) * 1998-05-15 1999-11-25 Aphton Corporation Method for the treatment of gastroesophageal reflux disease
WO2001012627A1 (en) * 1999-08-19 2001-02-22 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

Also Published As

Publication number Publication date
SI1513525T1 (sl) 2008-08-31
AU2003241585B2 (en) 2009-06-25
ZA200409908B (en) 2006-08-30
NO20050154L (no) 2005-01-11
SE0201943D0 (sv) 2002-06-20
MXPA04012659A (es) 2006-05-25
AU2003241585A1 (en) 2004-01-06
PL372186A1 (en) 2005-07-11
BR0311759A (pt) 2005-03-08
ES2304510T3 (es) 2008-10-16
PT1513525E (pt) 2008-06-24
DK1513525T3 (da) 2008-08-11
CN1662235A (zh) 2005-08-31
HK1075833A1 (en) 2005-12-30
RU2005101411A (ru) 2005-07-10
EP1513525A1 (en) 2005-03-16
JP2006507225A (ja) 2006-03-02
IS7654A (is) 2005-01-19
UA81627C2 (ru) 2008-01-25
CA2489730C (en) 2011-11-22
CY1107954T1 (el) 2013-09-04
IL165138A0 (en) 2005-12-18
RU2324484C2 (ru) 2008-05-20
WO2004000316A1 (en) 2003-12-31
JP4683920B2 (ja) 2011-05-18
DE60320990D1 (de) 2008-06-26
ATE395059T1 (de) 2008-05-15
JP2011068669A (ja) 2011-04-07
CA2489730A1 (en) 2003-12-31
NZ536559A (en) 2007-08-31
EP1513525B1 (en) 2008-05-14

Similar Documents

Publication Publication Date Title
CN100430056C (zh) Mglur5拮抗剂在制备治疗gerd的药物中的用途
EP2289518B1 (en) Therapeutic agent for inflammatory bowel disease
JP6145946B2 (ja) 併用ａｌｓ療法
JP2002508766A (ja) 心不全の治療方法
KR20010041110A (ko) 트라마돌을 함유하는 약제학적 배합물
JP3663202B2 (ja) 治療上の使用
KR20020070525A (ko) 디아미노트리플루오로메틸피리딘의 유도체를 함유하는소화기 질환 치료제 또는 예방제
JP2005511632A (ja) 胃食道逆流疾患の治療のための新しい使用
CN101316586A (zh) 5-ht4激动剂用于治疗可以由质子泵抑制剂诱导的胃排空延迟的用途
US7964609B2 (en) Use of mGluR5 antagonists for the treatment of gerd
KR20050024351A (ko) Ｇｅｒｄ 치료용 ｍｇｌｕｒ５ 길항제의 용도
EP1559446A1 (en) Treating agent for diarrhea-predominant irritable bowel syndrome
CN1744896B (zh) 结合有泰妥拉唑和组胺h2受体拮抗剂的药物组合物
HK1075833B (en) Use of mglur5 antagonists for the treatment of gerd
KR20150036115A (ko) 위식도 역류증에 대한 약제
BR112020005573A2 (pt) inibidor de mpges-1 para tratamento da dor de osteoartrite
WO2005058361A1 (en) USE OF mGluR1 ANTAGONISTS FOR THE TREATMENT OF GERD
JP2010120932A (ja) 経口用医薬組成物
US20080188512A1 (en) Treatment for irritable bowel syndrome
Dalal et al. Chronic nausea and vomiting
JP2007514788A (ja) 過敏性腸症候群の新規な処置ｉ
WO2005058326A1 (en) USE OF QUINAZOLINONE DERIVATIVES FOR THE INHIBITION OF TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS (TLESRs)
HK1119932A (en) Combinations comprising at least one direct thrombin inhibitor for the treatment of thrombosis
JP2007514741A (ja) 消化管障害の治療のための代謝調節型グルタミン酸受容体５（ｍＧＬｕＲ５）拮抗剤の使用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ASTRAZENCA AB

Free format text: FORMER OWNER: ASTRAZENCA AB; APPLICANT

Effective date: 20071214

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20071214

Address after: Swedish Sodertalje

Applicant after: Astra Zeneca Aktiebolag

Address before: Swedish Sodertalje

Applicant before: Astra Zeng Nica Co., Ltd.

Co-applicant before: NPS Pharmaceuticals, Inc.

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081105

Termination date: 20120619